Evaluation of the responsiveness of anti-VEGF treatment in DME

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29053

Enrollment

Registered

2020-02-26

Start date

2020-02-26

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy (DR)

Interventions

none

Eligibility

Inclusion criteria

Inclusion criteria: DME patients with completion of 6 intravitreal injections of anti-VEGF at UMCG and at least 1 year follow-up with BCVA and OCT after start of the treatment will be included.

Exclusion criteria

Exclusion criteria: high myopia (>6 diopters), glaucoma, media opacities interfering with OCT imaging, combined retinal disease, intraocular surgery within 12 weeks prior to the first injection, vitreomacular traction on SD-OCT and those whose SD-OCT images were of poor quality

Design outcomes

Primary

Measure	Time frame
treatment success	—

Secondary

Measure	Time frame
1 year BCVA and macular thickness	—

Contacts

Public ContactL.I. Los

University Medical Center Groningen

l.i.los@umcg.nl050-3612510

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)